Pharmaceutical compounds
PCT No. PCT/GB95/00300 Sec. 371 Date Nov. 4, 1996 Sec. 102(e) Date Nov. 4, 1996 PCT Filed Feb. 14, 1995 PCT Pub. No. WO95/21830 PCT Pub. Date Aug. 17, 1995Piperazine derivatives of formula (A): (A) wherein --- denotes an optional bond, provided that either --a-- and --c-- are both bonds and --b-- an...
Gespeichert in:
Hauptverfasser: | , , |
---|---|
Format: | Patent |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext bestellen |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | PCT No. PCT/GB95/00300 Sec. 371 Date Nov. 4, 1996 Sec. 102(e) Date Nov. 4, 1996 PCT Filed Feb. 14, 1995 PCT Pub. No. WO95/21830 PCT Pub. Date Aug. 17, 1995Piperazine derivatives of formula (A): (A) wherein --- denotes an optional bond, provided that either --a-- and --c-- are both bonds and --b-- and --d-- are not bonds, or --b-- and --d-- are both bonds and --a-- and --c-- are not bonds; each of R14 and R15 is independently selected from hydrogen and C1-C6 alkyl which is unsubstituted or substituted by an organic functional group; and each of R1 to R10, which may be the same or different, is independently hydrogen or an organic functional group; and the pharmaceutically acceptable salts and esters thereof have utility as modulators of multiple drug resistance (MDR). |
---|